Safety under the regulatory spotlight — 92 documents in 90 days

48 documents in the last 30 days alone

This concentration of recent safety publications may indicate a tightening cycle, or at least a period of heightened regulatory scrutiny around risk characterization, signal detection, and benefit-risk framing. Sponsors should consider that agencies may be emphasizing faster translation of emerging safety data into labeling, pharmacovigilance expectations, and post-market commitments, so companies with safety programs should be watching for shifts in class-wide warnings, stronger real-world evidence expectations, and more explicit scrutiny of data gaps or imbalances in adverse event reporting.